Morgan Stanley lowered the firm’s price target on Colgate-Palmolive (CL) to $96 from $104 and keeps an Overweight rating on the shares. Q2 results “should do little to change the debate on Colgate,” according to the analyst, who favors Coca-Cola (KO), Keurig Dr Pepper (KDP), Philip Morris (PM) and Monster Beverage (MNST) outside of health and personal care. However, Colgate remains a “relative” Overweight within household products, the analyst contends.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CL:
- Colgate-Palmolive’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating
- Colgate-Palmolive price target lowered to $83 from $88 at Wells Fargo
- Colgate-Palmolive price target lowered to $105 from $108 at Citi
- Colgate-Palmolive: Strategic Restructuring and Innovation Drive Buy Rating
- Colgate-Palmolive Reports Modest Q2 2025 Growth